Zoe Bollinger
Dec 9, 2014
•
Featured
Merck Plans to Continue with Cubist Acquisition Even After Loss of Key Patents
Today, Merck is scrambling to reassure investors about Cubist purchase after a federal judge yesterday afternoon invalidated four of five patents on Cubicin, an antibiotic that generated $967 million in sales last year and accounted for about 80% of Cubist sales, mostly in the U.S. The ruling means that generic versions can become available in 2016, at least three years earlier than expected.